Cerebrolysin · Research brief
Cerebrolysin vs Dihexa, Semax, P21 — Storage & Data
Short answer
Most neurotrophic research compounds ship as a white lyophilised powder that will sit in a freezer for a year without complaint. Cerebrolysin doesn't. It arrives already in solution, sealed in an amber ampoule, and that single formulation difference is why almost every honest comparison of cerebrolysin vs dihexa turns into a storage conversation before it turns into a pharmacology conversation.…
Key takeaways
- Cerebrolysin vs dihexa is a comparison between a heterogeneous porcine brain-derived peptide preparation and a single defined synthetic molecule, which is why their storage and analytical requirements barely overlap.
- Cerebrolysin ampoules are generally labelled for storage below 25°C protected from light, so refrigeration is a conservative choice rather than an absolute requirement, while freezing is actively discouraged.
- Freeze-thaw cycling is the most common handling error with Cerebrolysin, because aggregation can occur without any visible change in the solution.
- Lyophilised compounds including Dihexa, Semax and P21 hold at -20°C as sealed powder and shift to 2–8°C once reconstituted.
- Cerebrolysin carries decades of human clinical data with contested effect sizes; Dihexa and P21 remain preclinical, and Semax's clinical record sits largely outside Western trial registries.
- None of these compounds are FDA-approved drugs, and all are supplied for laboratory research use only.
Most neurotrophic research compounds ship as a white lyophilised powder that will sit in a freezer for a year without complaint. Cerebrolysin doesn't. It arrives already in solution, sealed in an amber ampoule, and that single formulation difference is why almost every honest comparison of cerebrolysin vs dihexa turns into a storage conversation before it turns into a pharmacology conversation.
We handle both categories daily, and the pattern is consistent. Labs rarely run into trouble with Cerebrolysin because they misread a mechanism. They run into trouble because a shipment sat on a loading dock, or because someone treated an aqueous solution like a lyophilised vial and put it in the freezer.
Does Cerebrolysin need to be refrigerated?
Cerebrolysin is supplied as a stabilised aqueous solution, and manufacturer labelling for the commercial ampoule generally specifies storage below 25°C with protection from light rather than mandatory refrigeration. For research stock, 2–8°C is the conservative default. Freezing is not recommended, because freeze-thaw cycles promote peptide aggregation in solution.
Here's what the label doesn't tell you: refrigeration and cold chain aren't the same question. A compound can be labelled for ambient storage and still be degraded by three days in a hot vehicle, because 'below 25°C' describes a steady state, not a tolerance for excursions. This page covers what's physically inside each compound, how cerebrolysin vs dihexa differ in handling and evidence, where Semax and P21 sit, and what to do when a shipment arrives warm.
What's actually inside each vial
The biggest reason cerebrolysin vs dihexa comparisons go sideways is that only one of them is a defined molecule. Cerebrolysin is a peptide preparation produced by standardised enzymatic breakdown of purified porcine brain proteins. It's a mixture: low-molecular-weight peptide fragments plus free amino acids, typically described as peptides under roughly 10 kDa. There is no single sequence to print on a certificate.
Dihexa is the opposite. It's N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, a synthetic angiotensin IV analogue developed out of Joseph Harding's laboratory at Washington State University, reported to act by potentiating hepatocyte growth factor (HGF) signalling at its receptor, c-Met. One sequence, one molecular weight, one identity test.
Semax is a synthetic heptapeptide analogue of the ACTH(4-10) fragment, Met-Glu-His-Phe-Pro-Gly-Pro, developed in Russia and widely reported to influence expression of BDNF (brain-derived neurotrophic factor). P21 is a synthetic peptidergic compound derived from the active region of ciliary neurotrophic factor (CNTF), developed in tau and neurogenesis research at the New York State Institute for Basic Research in Developmental Disabilities.
So when someone asks about p21 peptide vs cerebrolysin, or frames the decision as dihexa or cerebrolysin, they're weighing a heterogeneous biological hydrolysate against defined synthetic molecules. Different analytical problems. Different storage problems.
Why temperature, not chemistry, is the usual failure point
The mistake we see most often isn't contamination. It's freezing Cerebrolysin. People carry the habit over from lyophilised peptides, where -20°C is the default, and apply it to an amino-acid-rich aqueous solution. Freezing drives solute concentration gradients as ice forms, and the thaw can leave aggregated peptide that never fully redissolves. The solution can still look clear enough to pass a visual check while its fragment profile has shifted, and no bench-level inspection will reveal that.
That's the real answer to most cerebrolysin storage questions. The risk isn't warmth on its own, it's the transition. The same query runs in other languages, cerebrolysin oda sıcaklığı, literally 'cerebrolysin room temperature', and the answer doesn't change: steady ambient below 25°C, dark and sealed, is tolerated, while repeated cycling between a warm car and a cold fridge is not.
This is where cerebrolysin vs dihexa stops being an academic distinction. A sealed lyophilised powder holds at -20°C for extended periods because there's essentially no water available for hydrolysis. Once reconstituted, it becomes as fragile as any solution: 2–8°C, protected from light, short working window. That's why our Dihexa and P21 vials ship lyophilised, while Cerebrolysin ships as a cold-chain solution.
How much evidence sits behind each one
If depth of published human data is the deciding factor, cerebrolysin vs dihexa isn't a close contest. Cerebrolysin has been studied in ischaemic stroke, traumatic brain injury, vascular dementia and Alzheimer's disease for decades, across a large trial literature. Research suggests benefit in some populations, but systematic reviews have repeatedly flagged heterogeneity and uncertain effect sizes. Substantial literature, unsettled conclusions. It is not an FDA-approved drug.
Dihexa's record is preclinical. The rodent work reported by the Washington State University group underpins essentially all of the interest in it, and there is no substantial human trial record. Anyone weighing dihexa and cerebrolysin on evidence alone is comparing decades of clinical trials against animal studies.
Semax vs cerebrolysin splits differently. Semax has a long history of clinical use and research in Russia, where it's registered, but limited Western randomised controlled trial coverage. P21 vs cerebrolysin is the starkest gap of the three, since P21 remains preclinical.
On blood-brain barrier claims, treat marketing language sceptically. Cerebrolysin's low-molecular-weight fragments are proposed to cross. Dihexa was specifically engineered for lipophilicity and BBB penetration. Semax research has leaned heavily on intranasal delivery to bypass the barrier entirely. Proposed and demonstrated are not synonyms, and supplier copy blurs them constantly.
Cerebrolysin vs Dihexa, Semax and P21 at a Glance
The table sets the four side by side on the factors that actually change a sourcing or protocol decision: physical form, reported mechanism, storage default and evidence stage. Read the cerebrolysin vs dihexa rows together, because their handling requirements sit at opposite ends of the range.
| Compound | Form as supplied | Reported mechanism | Storage default | Evidence stage | Professional assessment |
|---|---|---|---|---|---|
| Cerebrolysin | Aqueous solution in sealed amber ampoules; a porcine brain-derived peptide preparation, not a single sequence | Neurotrophic-factor-like activity attributed to low-molecular-weight peptide fragments and free amino acids | Below 25°C protected from light per manufacturer labelling; 2–8°C is the conservative research default; do not freeze | The largest human clinical literature of the four, though stroke, TBI and dementia results remain mixed and contested | Best suited to work comparing against an existing clinical literature; accept that batch identity can never be defined by a single sequence |
| Dihexa | Lyophilised synthetic powder; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, an angiotensin IV analogue | Reported to potentiate hepatocyte growth factor signalling at the c-Met receptor | Sealed powder at -20°C; reconstituted solution at 2–8°C with a short working window | Preclinical rodent work from the Washington State University group; no substantial human trial record | The cleanest option for defined single-molecule mechanistic work where analytical identity must be exact |
| Semax | Synthetic heptapeptide analogue of ACTH(4-10); supplied as lyophilised powder or as a prepared spray solution | Reported to influence BDNF and NGF expression and monoamine signalling | Powder at -20°C; prepared solution refrigerated at 2–8°C and protected from light | Clinical use and research history in Russia; limited Western randomised controlled trial coverage | Reasonable middle ground on evidence, but published data is concentrated in one regulatory region and harder to cross-check |
| P21 | Synthetic peptidergic compound derived from the CNTF active region; lyophilised powder | Reported to promote neurogenesis and reduce tau hyperphosphorylation in mouse models | Sealed powder at -20°C; reconstituted at 2–8°C | Preclinical only, from tau and neurogenesis research at the New York State Institute for Basic Research | Narrow and specific; valuable for tau-focused models, thin ground for broad neurotrophic comparisons |
What If: Storage and Selection Scenarios
What if my Cerebrolysin shipment arrived warm?
Quarantine the batch and document the excursion before anything else. Note the ambient temperature, the transit duration and the condition of the cold pack, then check the supplier's certificate of analysis and stability guidance for that batch. A brief excursion within ambient labelling is a different event from 48 hours above 30°C, and the distinction only exists if you recorded it. Using unrecorded material introduces a variable you can't account for later in the data.
What if someone froze the ampoules?
Treat frozen Cerebrolysin as compromised stock rather than recoverable stock. Ice formation concentrates solutes at the freezing front, and the resulting aggregation is often irreversible on thaw even when the solution re-clarifies. Because the preparation is a mixture rather than a single sequence, a shifted fragment profile won't announce itself visually and can't be confirmed with a simple bench check.
What if the solution looks yellow or shows particles?
Stop and compare against the batch documentation instead of guessing. Cerebrolysin is normally a clear to slightly yellowish solution, so mild colouration may be within specification while visible particulate matter is not. Sealed ampoules that deviate from the certificate description should be set aside and raised with the supplier, with lot number and storage history attached.
What if I'm deciding between dihexa or cerebrolysin for a first study?
Let the analytical requirement decide, not the marketing. If the protocol depends on exact molecular identity, batch reproducibility and a clean mass spec trace, a defined synthetic like Dihexa is the workable choice. If the question is explicitly about a mixed neurotrophic preparation with an existing clinical comparison literature, cerebrolysin vs dihexa resolves the other way. The storage infrastructure you already have often settles it faster than the pharmacology does.
The uncomfortable truth about comparing these four
Let's be direct about this: cerebrolysin vs dihexa is not a like-for-like comparison, and treating it as one is a category error. You're holding a decades-old biological hydrolysate with a large, genuinely contested clinical literature next to a synthetic molecule whose entire reputation rests on rodent studies. Neither is interchangeable with the other, and no supplier can honestly tell you one is stronger. Everything here is research education about compounds sold for laboratory use only. If the question behind your search concerns a living patient, that belongs with a physician, and for an animal, with your veterinarian.
If you're sourcing for bench work, the batch documentation sits on each catalogue page, covering Cerebrolysin, Dihexa, P21, plus Semax Liquid Spray and Semax Amidate, with sequence and handling detail collected on our Semax reference page. Every batch is backed by a certificate of analysis, and the wider research peptide catalogue and company details are listed separately.
Cerebrolysin vs dihexa ultimately asks what kind of uncertainty you're prepared to carry. With Cerebrolysin, the uncertainty is compositional: you're working with a mixture whose exact fragment profile you can characterise but never fully specify, backed by a clinical record that argues with itself. With Dihexa, the molecule is unambiguous and the evidence is thin. Most labs pick based on mechanism. The ones that avoid wasted batches pick based on which uncertainty their protocol, and their fridge, can actually absorb.
References
Peer-reviewed sources on Cerebrolysin indexed in PubMed, listed for research context. Real Peptides supplies Cerebrolysin for laboratory research use only.
- Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. PMID 33515100. doi:10.1007/s10072-021-05089-2
- Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice. Neurochemical research, 2025. PMID 41460391. doi:10.1007/s11064-025-04627-0
- Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia. Molecular biology reports, 2025. PMID 40668305. doi:10.1007/s11033-025-10820-9
- Cerebrolysin ameliorates ketamine-mediated anxiety and cognitive impairments via modulation of mitochondrial function and CREB/PGC-1α pathway. Molecular brain, 2025. PMID 41204270. doi:10.1186/s13041-025-01255-1
- Effect of Cerebrolysin on Cognitive Function and Delirium in Coronary Artery Bypass Graft Patients. Medical science monitor : international medical journal of experimental and clinical research, 2025. PMID 40350671. doi:10.12659/MSM.947864
- Is Cerebrolysin Useful in Psychiatry Disorders?. Biomedicines, 2025. PMID 40722733. doi:10.3390/biomedicines13071661
- Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. Translational stroke research, 2025. PMID 40325343. doi:10.1007/s12975-025-01355-z
- Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke, 2025. PMID 39957612. doi:10.1161/STROKEAHA.124.049834
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA